The Government of the Bolivarian Republic of Venezuela through the Ministry of People’s Power for Health (MPPS) registered the Sputnik V vaccine against the coronavirus, under the procedure of authorization for emergency use, as announced by the Russian Direct Investment Fund (RDIF). It is worth mentioning that the country is carrying out clinical trials of the biological phase III.

“We welcome the decision of the Venezuelan Ministry of Health to approve the use of Sputnik V, a safe and effective vaccine to prevent the spread of the coronavirus. Sputnik V is now an important part of the national vaccine portfolios of several Latin American countries and we hope that in the coming weeks there will be more vaccine partnerships in the region,” said the director general of the Russian Direct Investment Fund, Kirill Dmitriev.

Key Benefits of Sputnik V:

The following aspects were taken into account for the registration

– Efficiency above 90%, with total protection against serious cases of COVID-19.

– It uses two different vectors for the two injections in a single vaccination course, providing longer-lasting immunity than vaccines that use the same delivery mechanism for both injections.

– The safety, efficacy and lack of long-term negative effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.

– There are no strong allergies caused by Sputnik V.

More than 1.5 million people vaccinated:

The developers of Sputnik V are working in collaboration with AstraZeneca on a joint clinical trial to improve the effectiveness of the vaccine from this laboratory.

Sputnik V has been approved in Russia, Belarus, Serbia, Argentina, Bolivia, Algeria and Palestine; while in the European Union the approval process has already begun.

The supply of the vaccine will be facilitated by the international partners of the Russian Direct Investment Fund in India, China, South Korea and other countries.